The Cancer Molecular Therapeutics Research Association Board of Directors is pleased to announce the location of the
2024 CMTRA conference at
Granlibakken Tahoe Resort in Lake Tahoe, California.
The conference is scheduled for July 14th - 18th, 2024.
The CMTRA is excited to share more news about registration and program details soon!
ABOUT THE CANCER MOLECULAR THERAPEUTICS RESEARCH ASSOCIATION
The Full Story
Provides a dynamic platform for the most contemporary and controversial approaches to the treatment of cancer
Dedicates half of the formal presentation time to questions and answers to promote rigorous discussion
Welcomes an active dialog among investigators from industry, academia, government and, foundations
Enables informal and intimate (150 participants) networking for graduate students, postdoctoral fellows, residents and, early-stage and established investigators
Awards the top four poster presenters with the opportunity to orally present their research and attend next year’s conference free of charge
Builds on the legacy of more than two decades of annual conference
The 2022 and 2023 CMTRA Conferences have both been remarkable events. The CMTRA Board and event team are excited about the 2024 Annual Conference to come!
See below for pictures from the 2022 and 2023 CMTRA Annual Conferences.
The Cancer Molecular Therapeutics Research Association [CMTRA] was created in 2008 to organize and host the annual Molecular Therapeutics of Cancer meeting. The meeting objective is to provide a forum for presentation and discussion of contemporary research in the field of cancer drug development and therapy. Modeled after small Gordon-type conferences, the meeting provides an opportunity for young and established researchers to discuss and challenge current paradigms for cancer drug development and therapy, as well as a venue where novel ideas can be presented with anticipation of lively debate.
Officers & Board Members
Emeritus Board Members:
James D. Winkler, Ph.D. - Cheif Scientific Officer | OnKure Therapeutics | Boulder, Colorado
Mary-Ann Bjornsti, Ph.D. - Professor Department of Pharmacology & Toxicology | University of Alabama at Birmingham | Birmingham, AL
Peter Houghton, Ph.D. - Greehey Children's Cancer Research Institute | UT Health at San Antonio | San Antonio, TX
Phillip Dennis, M.D., Ph.D. - Sanofi Oncology |
James Winkler, Ph.D. - OnKure Therapeutics | Boulder, CO
Robert Kramer, Ph.D. - RAKramer Consulting LLC | Newton, PA
Alan Eastman, Ph.D. - Professor Emeritus | Norris Cotton Cancer Center | Dartmouth College | Hanover, NH
John A. Hickman, D.Sc. - Agon Consulting, Paris
Branimir I. Sikic, M.D. - Director | Stanford Clinical & Translational Research Unit; Co-director | Stanford University School of Medicine | Stanford, CA
MARTIN MCMAHON, PH.D.
Cumming-Presidential Professor of Cancer Biology & Senior Director for Preclinical Translation | Huntsman Cancer Institute & Dept. of Dermatology | University of Utah | Salt Lake City, UT
LORI FRIEDMAN, PH.D.
Chief Scientific Officer | ORIC Pharmaceuticals | South San Francisco, CA
WILLIAM J. PLACZEK, PH.D.
Associate Professor | Department of Biochemistry and Molecular Genetics; Director | Central Alabama High-Field NMR Facility; Co-Director | Structural Biology Shared Facility, Cancer Center | The University of Alabama at Birmingham
SHIVA MALEK, PH.D.
Global Head, Oncology | Novartis Institute of Biomedical Research
ARIA VAISHNAVI, PH.D.
Assistant Professor | Department of Cancer Biology | University of Texas MD Anderson Cancer Center
EMMA LEES, PH.D.
Head, Mechanisms of Cancer Resistance Thematic Research Center | Bristol Myers Squibb
ELI M. WALLACE, PH.D.
Chief Scientific Officer, Oncology | BridgeBio | Dallas, TX
BOB ABRAHAM, PH.D.
Executive Vice President | Head of Cancer Biology | Odyssey Therapeutics
ZAHID H. SIDDIK, PH.D.
Professor of Medicine | Pharmacology Department of Experimental Therapeutics | MD Anderson Cancer Center | Houston, TX